Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis

Bibliography

• Lund KJ. Menopause and the menopausal transition. Med Clin North Am 2008;92:1253-71
   PubMed Web of Science ®Google Scholar
• Nelson HD. Menopause. Lancet 2008;371:760-70
   PubMed Web of Science ®Google Scholar
• Patten RD, Karas RH. Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc Med 2006;16:69-75
   PubMed Web of Science ®Google Scholar
• ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12(5):483-97
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302
   PubMed Web of Science ®Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-9
   Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399-411
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• Gustafsson JA. Estrogen receptor beta–a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379-83
   PubMed Web of Science ®Google Scholar
• Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005;328:688-96
   PubMed Web of Science ®Google Scholar
• Pacifici R. Mechanisms of estrogen action in bone. In: Bilezikian JP, Raisz LG, Martin TJ, editors, Principles of bone biology. 3rd edition. Elsevier, Inc., USA; 2008. p. 921-33
   Google Scholar
• Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010;95:3569-77
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61
   PubMed Web of Science ®Google Scholar
• Martin TJ, Seeman E. Bone remodeling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab 2008;22:701-22
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;2:1151-4
   PubMed Web of Science ®Google Scholar
• Bush TL, Wells HB, James MK, Effects of hormone therapy on bone mineral density—results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
   PubMed Web of Science ®Google Scholar
• Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Curr Osteoporos Rep 2007;5:153-9
   PubMedGoogle Scholar
• Grodstein F, Manson JE, Colditz GA, A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, Women's Health Initiative InvestigatorsEstrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R. Breast cancer and hormonal replacement therapy. Ann NY Acad Sci 2003;997:341-50
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-8
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American menopause society. Menopause 2008;15(4):584-602
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Nuti R. Perspectives in the treatment and prevention of osteoporosis. Drugs Today (Barc) 2009;45:629-47
   PubMed Web of Science ®Google Scholar
• Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs 2001;6:137-54
   PubMedGoogle Scholar
• Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer (Eight Cain Memorial award lecture). Cancer Res 1990;50:4177-89
   PubMed Web of Science ®Google Scholar
• Jordan VC. Chemosuppression of breast cancer with tamoxifen -laboratory evidence and future clinical investigations. Cancer Investig 1988;6:589-95
   PubMed Web of Science ®Google Scholar
• Avioli LV. SERM Drugs for the prevention of osteoporosis. Trends Endocrinol Metab 1999;10:317-19
   PubMed Web of Science ®Google Scholar
• Riggs L, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005;96:15-25
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-79
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, De Paola V, Nuti R. Raloxifene in breast cancer prevention. Expert Opin Drug Saf 2008;7:259-70
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Whitaker MD, Nickelsen T, Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-54
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637-45
   PubMed Web of Science ®Google Scholar
• Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987;10:31-5
   PubMed Web of Science ®Google Scholar
• Love RR, Barden HS, Mazess RB, Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Gunness M, Muchmore DB, A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Parfitt AM, Marcus R, Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-22
   PubMed Web of Science ®Google Scholar
• Rosati RL, Da Silva Jardine P, Cameron KO. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998;41:2928-31
   PubMed Web of Science ®Google Scholar
• Yang X, Reinhold AR, Rosati RL, Liu KK. Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator. Org Lett 2000;2:4025-7
   PubMed Web of Science ®Google Scholar
• Gennari L. Lasofoxifene (Pfizer). Curr Opin Investig Drugs 2005;6:1067-78
   PubMedGoogle Scholar
• Gennari L, Merlotti D, De Paola V, Nuti R. Lasofoxifene: evidence of its therapeutic value in osteoporosis. Core Evid 2010;4:113-29
   PubMedGoogle Scholar
• Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin Interv Aging 2010;5:19-29
   PubMed Web of Science ®Google Scholar
• Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-72
   PubMed Web of Science ®Google Scholar
• Jhonson KA, Gardner MJ, Prakash C. In vivo and in vitro metabolites of a next-generation selective estrogen receptor modulator, lasofoxifene, in humans. Drug Metab Rev 2004;36:246
   Web of Science ®Google Scholar
• Katzenellenbogen JA. D- 1,2-Dyaril-3,4-dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor. J Steroid Biochem 1985;23:929-37
   PubMedGoogle Scholar
• Gardner M, Nishizawa Y, Wei G, A single-dose pharmacokinetic study of lasofoxifene in japanese and caucasian postmenopausal women. J Bone Miner Res 2004;19: abstract M469
   Web of Science ®Google Scholar
• Gardner M, Taylor A, Wei G, Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol 2006;46:52-8
   PubMed Web of Science ®Google Scholar
• Roman D, Bramson C, Ouellet D, Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. J Clin Pharmacol 2005;45:1407-12
   PubMed Web of Science ®Google Scholar
• Moller R, Fisher J, Taylor A, Effect of food on the pharmacokinetics of lasofoxifene, in healthy postmenopausal women. J Bone Miner Res 2004;19: abstract SU487
   PubMed Web of Science ®Google Scholar
• Moller RA, Fisher JM, Taylor AE, Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. Ann Pharmacother 2006;40:32-7
   PubMed Web of Science ®Google Scholar
• Bramson C, Ouellet D, Roman D, A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J Clin Pharmacol 2006;46:29-36
   PubMed Web of Science ®Google Scholar
• Ke HZ, Paralkar VM, Grasser WA. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139:2068-76
   PubMed Web of Science ®Google Scholar
• Ke HZ, Qi H, Chidsey-Frink KL, Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. J Bone Miner Res 2000;15:S1-S310
   Web of Science ®Google Scholar
• Ke HZ, Foley GL, Simmons HA, Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005
   PubMed Web of Science ®Google Scholar
• Ke HZ, Qi H, Crawford DT, Lasofoxifene (CP-336-156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 2000;141:1338-44
   PubMed Web of Science ®Google Scholar
• Ke HZ, Oi H, Chidsey-Frink KL, Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 2001;16:765-73
   PubMed Web of Science ®Google Scholar
• Kharode YP, Green PD, Marzolf JT, Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate, co-treatment on h-PTH-induced reversal of established osteopenia in ovariectomized rats [abstract SU387]. J Bone Miner Res 2003;18:S273
   Web of Science ®Google Scholar
• Cohen LA, Pittman B, Wang CX, LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001;61:8683-8
   PubMed Web of Science ®Google Scholar
• Chesworth R, Zawistoski MP, Lefker BA, Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg Med Chem Lett 2004;14:2729-33
   PubMed Web of Science ®Google Scholar
• Cappon GD, Horimoto M, Hurtt ME. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. Birth Defects Res B Dev Reprod Toxicol 2004;71:142-9
   PubMed Web of Science ®Google Scholar
• Terry KK, Cappon GD, Hurtt ME, Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats. Birth Defects Res B Dev Reprod Toxicol 2004;71:150-60
   PubMed Web of Science ®Google Scholar
• Weisenburger WP, Hagler AR, Tassinari MS. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 2004;71:171-84
   PubMed Web of Science ®Google Scholar
• Ozolins TRS, Gupta U. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2004;71:161-70
   PubMed Web of Science ®Google Scholar
• Cohen IR, Wierda D, Griffey KI, The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats. Reprod Toxicol 1998;12:271-88
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-01-FDA.pdf [Last accessed 20 September 2010]
   Google Scholar
• Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf [Last accessed 20 September 2010]
   Google Scholar
• Lee A, Radecki D, Wolter K, Lasofoxifene phase 2 and phase 3 clinical trial design and strategy. J Bone Miner Res 2005;20: abstract M384
   Web of Science ®Google Scholar
• Day W, Martel J, Lee A. Lasofoxifene phase 2 dose response analysis in postmenopausal women. J Bone Miner Res 2005;20: abstract M385
   Web of Science ®Google Scholar
• Moffett AH, Ettinger M, Bolognese M, Lasofoxifene, a next generation SERM, is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women. J Bone Miner Res 2004;19: abstract SA426
   PubMed Web of Science ®Google Scholar
• Portman DJ, Moffett AH, Bachman GA, Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy. Obstet Gynecol 2004;103:25S-6S
   Web of Science ®Google Scholar
• McClung MR, Siris E, Cummings S, Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-86
   PubMed Web of Science ®Google Scholar
• McClung M, Siris E, Cummings S, Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Miner Res 2005;20: abstract F429
   Web of Science ®Google Scholar
• Davidson M, Moffett A, Welty F, Extraskeletal effects of lasofoxifene on postmenopausal women. J Bone Miner Res 2005;20: abstract SA428
   Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;62:686-96
   Web of Science ®Google Scholar
• Goldstein SR, Neven P, Cummings S, Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes. Menopause 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• McClung M, Portman D, Emkey R, Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Res 2004;19: abstract SA423
   PubMed Web of Science ®Google Scholar
• Goldstein SR. Not all SERMs are created equal. Menopause 2006;13:325-7
   PubMed Web of Science ®Google Scholar
• Wang XN, Simmons HA, Salatto CT, Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause 2006;13:609-20
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Pre-Authorisation Evaluation of Medicines for Human Use. Committee for Medicinal Products for Human Use summary of positive opinion for Fablyn. London, 18 December 2008. Doc.Ref. EMEA/CHMP/609979/2008
   Google Scholar
• Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35
   PubMed Web of Science ®Google Scholar
• Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 2010;362:752-4
   PubMed Web of Science ®Google Scholar
• Stevenson N, Jones ML, De Nigris E, A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160
   PubMed Web of Science ®Google Scholar